CHARLES E. PETERSEN, Ph.D.

816 Larchwood Drive

Brea, California 92821
Home (714) 674-0503
Cell (714) 975-4490
cpf32d0e@westpost.net

PROFESSIONAL PROFILE
Director of Formulations and Biopharmaceuticals with a growing pharmaceutical co
ntract organization. Leader with extensive technical and managerial experience.
Practical and creative with proven ability to initiate and develop technical te
ams and manage complex technical projects. Experience includes:
* Project management in high pressure complex environments
(multiple unique drug product development programs managed
simultaneously in a CRO environment)
* Technology transfer to manufacturing (scale-up, drafting batch
records)
* Cross functional team management (managed teams with up to
20 people)
* Ability to deliver high quality presentations to senior management
and customers in support of business objectives
* Preparation of high quality technical/regulatory documents to
support business objectives
* Ability to focus diverse technical teams to meet defined business
goals within firm timelines
* Biopharmaceutical and small molecule product development
* Drug product formulation development
* Extensive record of scientific accomplishments in industry and
academia
* Over 200 development reports to support FDA applications

PROFESSIONAL EXPERIENCE
MEDOMICS
2009 to Present
ASUZA, CALIFORNIA
Chief Technology Officer
Contribute technical aspects to company strategic vision. Develop new technologi
es. Launch new genetic tests for use in the clinic. Direct all laboratory operat
ions.
* Direct laboratory operations
* Develop clinical genetic tests
* Next Generation DNA sequencing
* Write SBIR grants
IRVINE PHARMACEUTICAL SERVICES
2006 to 2009
IRVINE, CALIFORNIA
Director, Formulations and Biopharmaceutical Services
Hired to develop new formulations department at a fully compliant cGMP CRO. Sup
ervised merger of biopharmaceutical and formulations departments. Recruited and
trained 10 personnel for new department. Generated 2.4 million annually in formu
lation project work. Experience includes:
* Lyophilization cycle development
* Liquid formulations
* Solid dosage forms
* Emulsions and suspension formulations
* Topical formulations
* Liposome formulations
* Protein and peptide drugs
* Oligonucleotide drugs
* Method development and validation
* Routine laboratory troubleshooting
* Stability study management
* Customer communication
* Technical writing
* 10 direct reports

CARDINAL HEALTH
2004 to 2006
SAN DIEGO, CALIFORNIA
Senior Scientist
A fully-compliant cGMP CRO offering services that include method development and
validation, analytical chemistry, stability storage and testing, comprehensive
microbiological support, preformulation and formulation, drug delivery testing,
inhalation and biopharmaceutical support. Experience includes.
* Small molecule and biopharmaceutical method development
* Protein and peptide drugs
* Oligonucleotide drugs
* Method validation
* Stability program management
* Lyophilization cycle development
* Managed 5 direct reports
* Technical writing

CHEMICAL DIVERSITY LABS

2002 to 2004
SAN DIEGO, CALIFORNIA
Senior Scientist
A chemistry CRO, synthesizing and screening chemical libraries to generate new l
ead compounds for drug product development. Experience includes.
* Developing Elisa assays for customer enzyme targets
* Screening chemical libraries in high throughput environment for
enzyme inhibition
* Writing small business administration grants.
UNIVERSITY OF HAWAII
1997 to 2002
HONOLULU, HAWAII
Assistant Professor
Duties included managing graduate student projects, writing grants, publishing s
cientific articles and teaching medical students. Experiences included.
* Protein expression
* Protein purification
* Protein characterization
* DNA cloning
* Advanced spectroscopy
* Molecular assay design
* Site-directed mutagenesis
* Laboratory troubleshooting
* Managed three graduate student projects
* 22 publications in peer-reviewed scientific journals
* Developed and taught new course on molecular medicine
* Developed assays to screen patient samples for genetic mutations
associated with disease
CALIFORNIA INSTITUTE OF BIOLOGICAL RESEARCH
1990 to 1992
SAN DIEGO, CALIFORNIA
Supervising Technician
Duties included PCR mapping and DNA sequencing for bacterial and animal strain i
dentification.
Experiences included:
* 2 publications in peer-reviewed scientific journals
* Protein purification
* Nucleic acid chemistry
* DNA cloning
* Electrophoresis
* DNA sequencing
* Advanced PCR techniques
TELIOS PHARMACEUTICALS
1988 to 1990
LA JOLLA, CALIFORNIA
Technician
Purified the IIb/IIIa membrane receptor from expired blood. Incorporated membran
e receptor into liposomes. Screened peptides for inhibition of membrane receptor
binding to extracellular membrane proteins. Conducted ex-vivo studies on platel
et aggregation inhibition in whole blood by peptides identified as drug candidat
e from in vitro assay.
Experiences included.
* Protein purification
* Assay design
* Liposomes

EDUCATION
Ph.D. Biochemistry University of HI, Manoa 1997
B.A. Biochemistry University of CA, Berkeley 1988

PUBLICATIONS
1. J. Welsh, C. Petersen and M. McClelland. Polymorphisms generated by arbitrari
ly primed PCR in the mouse: application to strain identification and genetic map
ping. Nucleic Acids Research 19(2), 303-06, 1991.
2. M. McClelland, C. Petersen and J. Welsh. Length polymorphisms in the tRNA int
ergenic spacers detected by using the polymerase chain reaction can distinguish
streptococcal strains and species. J. Clin. Microbiol. 30(6), 1499-1504, 1992
3. C.E. Petersen, A.G. Scottolini, LR. Cody, M. Mandel, N. Reimer and N.V. Bhaga
van. A point mutation in the human serum albumin gene results in familial dysalb
uminemic hyperthyroxinemia. J. Med. Gen. 31, 355-59, 1994
4. C.E. Petersen, M. Mandel and N.V. Bhagavan. Expression of a human serum album
in variant with high affinity for thyroxine. Biochem. Biophys. Res. Commun. 214(
3), 1121-29, 1995.
5. C.E. Petersen, C-E. Ha, D.M. Jameson and N.V. Bhagavan. Mutations in a specif
ic human serum albumin thyroxine binding site define the structural basis of fam
ilial dysalbuminemic hyperthyroxinemia. J. Biol. Chem. 271, 19110-17, 1996.
6. C.E. Petersen, C-E. Ha, K. Harohalli, D. Park and N.V. Bhagavan. Mutagenesis
studies of thyroxine binding to human serum albumin define an important structur
al characteristic of subdomain 2A. Biochemistry 36, 7012-17, 1997.
7. M.K. Helms, C.E. Petersen, N.V. Bhagavan and D.M. Jameson. Time-resolved fluo
rescence studies on site-directed mutants of human serum albumin. FEBS letters 4
08, 67-70, 1997.
8. N.V. Bhagavan and C.E. Petersen. A novel screening approach to the modulation
of unfavorable human serum albumin/drug interactions. Emerging Therapeutics 2(1
), 155-58, 1998.
9. N.V. Bhagavan and C.E. Petersen. Human serum albumin as a binding agent for d
etoxification of the blood. Emerging Therapeutics 2(1), 159-61, 1998.
10. C.E. Petersen, C-E. Ha, K. Harohalli, D.S. Park, J.B. Feix, O. Isozaki and N
.V. Bhagavan. Structural investigations of a new familial dysalbuminemic hyperth
yroxinemia genotype. Clin. Chem. 45(8), 1248-54, 1999.
11. C-E. Ha, C.E. Petersen, D.S. Park, K. Harohalli and N.V. Bhagavan. Identific
ation of key amino acid residues involved in specific interactions between digox
in and human serum albumin. J. Biochem. Mol. Biol. and Biophys.. 2, 201-07, 1999
.
12. D.S. Park, C.E. Petersen, C-E. Ha, K. Harohalli, J.B. Feix and N.V. Bhagavan
. Expression of a human serum albumin fragment (consisting of subdomains IA, IB,
and IIA) and a study of its properties. IUBMB Life, 48, 169-74, 1999.
13. C-E. Ha, C.E. Petersen, D.S. Park, K. Harohalli and N.V. Bhagavan. Investiga
tions of the effects of ethanol on warfarin binding to human serum albumin. J Bi
omed. Sci., 7(2), 114-21, 2000.
14. C.E. Petersen, C-E. Ha, K. Harohalli, D.S. Park and N.V. Bhagavan. Familial
dysalbuminemic hyperthyroxinemia may result in altered warfarin pharmacokinetics
.
Chemico-Biological Interactions, 124, 161-72, 2000.
15. C.E. Petersen, C-E. Ha, K. Harohalli, J.B. Feix and N.V Bhagavan. A dynamic
model of bilirubin binding to human serum albumin. J. Biol. Chem., 275, 20985-95
, 2000.
16. R.G. Eckenhoff, C.E. Petersen, C-E. Ha and N.V. Bhagavan. Inhaled anestheti
c binding sites in human serum albumin. J. Biol. Chem., 275, 30439-45, 2000.
17. K. Harohalli, C.E. Petersen, C-E. Ha, J. B. Feix and N.V. Bhagavan. Tryptoph
an 214 of human serum albumin is the primary target for nitrosation in human pla
sma. Journal of Biomedical Science 9, 47-58, 2002.
18. J. Yang, C.E. Petersen, C-E. Ha and N.V. Bhagavan. Structural insights into
human serum albumin-mediated prostaglandin catalysis. Prot. Sci. 11, 538-45, 20
02.
19. C.E. Petersen, C-E. Ha, S. Curry and N.V. Bhagavan. Probing the structure o
f the warfarin-binding site on human serum albumin using site-directed mutagenes
is. Proteins 47, 116-25, 2002.
20. R. Subramaniam, X.J. Fan, V. Scivitarro, J. Yang, C-E. Ha, C.E. Petersen, W.
Surewicz, N.V. Bhagavan, M.F. Weiss and V.M. Monnier. Cellular oxidant stress a
nd advanced glycation endproducts of albumin: Caveats of the dichlorofluorescein
assay. Arch. Biochem. Biophys. 400, 15-25, 2002.
21. R. Liu, R. Pidikitti, C-E. Ha, C.E. Petersen, N.V. Bhagavan and R.G. Eckenh
off. The role of electrostatic interactions in human serum albumin binding and s
tabilization by halothane. J. Biol. Chem. 277, 36373-9, 2002.
22. J.S. Ha, C-E. Ha, J.T. Chao, C.E. Petersen, A. Theriault and N.V. Bhagavan.
Human Serum Albumin and its structural variants mediate cholesterol efflux from
cultured endothelial cells. Biochim. Biophys. Acta 1640 (2-3), 119-28 (2003).
23. I. Petitpas, C.E. Petersen, C-E. Ha, A.A. Bhattacharya, P.A. Zunszain, J. Gh
uma, N.V. Bhagavan, S. Curry. Stuctural basis of albumin-thyroxine interactions
and familial dysalbuminemic hyperthyroxinemia. Proc. Natl. Acad. Sci. 100(11) (2
003).
24. A. Siemiarczuk, C.E. Petersen, C-E. Ha, J. Yang, N.V. Bhagavan. Analysis of
tryptophan fluorescence lifetime in a series of human serum albumin mutants with
substitutions in subdomain 2A. Cell Biochem. Biophys. 40(2), 115-22 (2004).

AWARDS
1. Honors in general scholarship (University of California Berkeley
1983-1988)
2. Honors in Biochemistry department (University of California,
Berkeley 1988)
3. Kotobuki Fellowship (University of Hawaii, Manoa 1992-1997)
4. Outstanding graduate student award (FAOBMB 1994)
5. Young medical scientists training award (FASEB 1997)
6. Medical sciences scholar of the year (ARCS 1997)
7. Biomedical sciences symposium best poster award (University of
Hawaii 1993)
8. American Heart Association best poster award (Hawaii Heart
1997)
PATENTS
1. N.V. Bhagavan, C.E. Petersen, M. Mandel. Nucleic acids encoding a mutant form
of human serum albumin involved in familial dysalbuminemic hyperthyroxinemia.
U. S. patent # 5,589,338 (1996).
2. N.V. Bhagavan, C.E. Petersen, M. Mandel. Thyroxin-binding HSA fragments.
U.S. patent # 5,698,517 (1997).
FUNDED RESEARCH GRANTS
1. Hawaii Community Foundation 1997 Development of thyroxine binding mutants of
human serum albumin as a treatment for hyperthyroidism. $50,000.
2. American Heart Association 1997-1998 Cardiovascular studies of human serum al
bumin/ligand interactions $80,000.
3. American Heart Association 1999-2001 Cardiovascular studies of human serum al
bumin/ligand interactions $100,000.
REFERENCES
Available upon request.